Company profile
Evaxion A/S
NASDAQ:EVAXBiotechnology: Biological Products (No Diagnostic Substances)
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05309421 | phase2 | active_not_recruiting | 2022-09-19 | 2025-09-30 | Evaxion Biotech A/S | A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma |
| NCT04455503 | phase1_2 | terminated | 2020-07-13 | 2023-02-28 | Evaxion Biotech A/S | Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 |
FDA applications (0)
No records yet.